CA3196911A1

CA3196911A1 - Compositions and methods for sublingual delivery of nicotine

Info

Publication number: CA3196911A1
Application number: CA3196911A
Authority: CA
Inventors: John Docherty; Christopher Andrew Bunka
Original assignee: Poviva Corp
Current assignee: Poviva Corp
Priority date: 2022-03-22
Filing date: 2023-03-20
Publication date: 2023-07-12
Anticipated expiration: 2043-03-20
Also published as: CA3196911C; JP2024514731A; EP4274437A1; MX2023009660A

Abstract

Disclosed herein are compositions and methods for oral delivery of nicotine and nicotine derivatives.
In one embodiment the nicotine is delivered in an oral packets, pouches, or sachets.

Description

ATTORNEY DOCKET NO. 07341.020W01 COMPOSITIONS AND METHODS FOR SUBLINGUAL DELIVERY OF NICOTINE
FIELD
Disclosed herein are compositions and methods for oral delivery of nicotine and nicotine derivatives. In one embodiment the nicotine is delivered in an oral packets, pouches, or sachets.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is a plot of the individual plasma concentrations (ng/mL) for Nicotine versus time (hour) after buccal administration of the nicotine benzoate control composition disclosed in TABLE I in male Beagle dogs.
Figure 2 is a plot of the mean plasma concentration (ng/mL) for Nicotine versus time (hour) after buccal administration of nicotine benzoate control composition disclosed in TABLE I in male Beagle dogs.
Figure 3 is a plot of the individual plasma concentrations (ng/mL) for Nicotine versus time (hour) after buccal administration of the disclosed nicotine benzoate composition disclosed in Table 11 (4 mg) in male Beagle dogs.
Figure 4 is a plot of the mean plasma concentration (ng/mL) for Nicotine versus time (hour) after buccal administration of the disclosed compound in Table II (4 mg) in male Beagle dogs.
Figure 5 is a plot of the individual plasma concentrations (ng/mL) for Nicotine versus time (hour) after buccal administration of the nicotine polacrilex control composition disclosed in TABLE III (4 mg) in male Beagle dogs (Group 3).
Figure 6 is a plot of the mean plasma concentration (ng/mL) for Nicotine versus time (hour) after buccal administration of the nicotine polacrilex control composition disclosed in TABLE III (4 mg) in Male Beagle dogs (Group 3) Figure 7 is a plot of the individual plasma poncentrations (ng/mL) for Nicotine versus time (hour) after buccal administration of the nicotine polarcilex composition disclosed in TABLE VI (4 mg) in male Beagle dogs (Group 4).
Figure 8 is a plot of the mean plasma concentration (ng/mL) for Nicotine versus time (hour) after buccal administration of the nicotine polarcrilex composition disclosed in TABLE
VI (4 mg) in male Beagle dogs (Group 4).
DETAILED DESCRIPTION OF THE DISCLOSURE

ATTORNEY DOCKET NO. 07341.020W01 The materials, compounds, compositions, articles, and methods described herein may be understood more readily by reference to the following detailed description of specific aspects of the disclosed subject matter and the Examples included therein.
Also, throughout this specification, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which the disclosed matter pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.
General Definitions In this specification and in the claims that follow, reference will be made to a number of terms, which shall be defined to have the following meanings:
All percentages, ratios and proportions herein are by weight, unless otherwise specified.
All temperatures are in degrees Celsius ( C) unless otherwise specified.
The terms "a" and "an" are defined as one or more unless this disclosure explicitly requires otherwise.
Ranges may be expressed herein as from "about" one particular value, and/or to "about"
another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.
The terms "comprise" (and any form of comprise, such as "comprises" and "comprising"), "have" (and any form of have, such as "has" and "having"), "include" (and any form of include, such as "includes" and "including") and "contain" (and any form of contain, such as "contains" and "containing") are open-ended linking verbs. As a result, an apparatus that "comprises," "has," "includes" or "contains" one or more elements possesses those one or more elements, but is not limited to possessing only those elements. Likewise, a method that "comprises," "has," "includes" or "contains" one or more steps possesses those one or more steps, but is not limited to possessing only those one or more steps.
Any embodiment of any of the disclosed methods or compositions can consist of or consist essentially of ¨ rather than comprise/include/contain/have ¨ any of the described steps,

2 ATTORNEY DOCKET NO. 07341.020W01 elements, and/or features. Thus, in any of the claims, the term "consisting of" or "consisting essentially of" can be substituted for any of the open-ended linking verbs recited above, in order to change the scope of a given claim from what it would otherwise be using the open-ended linking verb.
The feature or features of one embodiment may be applied to other embodiments, even though not described or illustrated, unless expressly prohibited by this disclosure or the nature of the embodiments.
Any embodiment of any of the disclosed compounds or methods can consist of or consist essentially of ¨ rather than comprise/include/contain/have ¨ any of the described steps, elements, and/or features. Thus, in any of the claims, the term "consisting of" or "consisting essentially of" can be substituted for any of the open-ended linking verbs recited above, in order to change the scope of a given claim from what it would otherwise be using the open-ended linking verb.
For the purposes of the present disclosure the terms "sublingual" and "buccal"
are used interchangeably. The definition of "sublingual" is administration of a drug under the tongue to be absorbed by the tissue therein. The definition of "buccal" is to administer a drug by placing it between your cheek and gum. For the purposes to the present disclosure the user can either place the disclosed compositions under the tongue of between the check and gum, whichever mode of delivery is more convenient. Therefore, the disclose compositions can be absorbed in any manner chosen by the user.
The feature or features of one embodiment may be applied to other embodiments, even though not described or illustrated, unless expressly prohibited by this disclosure or the nature of the embodiments.
A smokeless oral nicotine product can be provided to the user in a portioned or a non-portioned format. Portioned smokeless oral nicotine products can reduce or eliminate the handling of the tobacco by the user, which can offer significant advantages in terms of better hygiene, convenience and/or ease of use.
Disclosed herein are compositions for sublingual delivery of nicotine. Unlike orally delivered compositions, sublingual compositions are absorbed in the mucosa of the mouth and therefore avoid the side effect of direct contact of nicotine with the stomach, intestines and other digestive organs.

3 ATTORNEY DOCKET NO. 07341.020W01 Disclosed herein are base compositions for sublingual or buccal delivery of nicotine, comprising:
a) from about 1% to about 6% by weight of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof;
b) from about 3% to about 20% by weight of sunflower oil;
c) from about 10% to about 20% by weight of sodium bicarbonate; and d) the balance one or more carriers.
The disclosed compositions do not comprise an organic or inorganic acid. In addition, the compositions are free flowing solids containing less than 0.01% by weight moisture.
One aspect of the disclosed compositions, comprises:
a) from about 1% to about 3.5% by weight of nicotine, a nicotine salt, or mixtures thereof;
b) from about 3% to about 10.5% by weight of sunflower oil;
c) from about 10% to about 20% by weight of sodium bicarbonate; and d) the balance one or more carriers.
In one non-limiting embodiment of this aspect the base compositions, comprise:
a) from about 1% to about 3.5% by weight of nicotine, a nicotine salt, or mixtures thereof;
b) from about 3% to about 10.5% by weight of sunflower oil;
c) from about 10% to about 20% by weight of sodium bicarbonate; and d) the balance an admixture of microcrystalline cellulose and inulin.
The disclosed base compositions can comprise from about 1% to about 6% by weight of nicotine, a nicotine salt or nicotine in combination with a resin. In one embodiment, the base composition can comprise from about 1% to about 5% by weight of nicotine, a nicotine salt or nicotine in combination with a resin. In another embodiment, the base composition can comprise from about 2% to about 6% by weight of nicotine, a nicotine salt or nicotine in combination with a resin. In a further embodiment, the base composition can comprise from about 2% to about 5% by weight of nicotine, a nicotine salt or nicotine in combination with a resin. In a yet further embodiment, the base composition can comprise from about 3% to about 5% by weight of nicotine, a nicotine salt or nicotine in combination with a resin. For example, the amount of nicotine, a nicotine salt or nicotine in combination with a resin can be 1%, 2%,

4 ATTORNEY DOCKET NO. 07341.020W01 3%, 4%, 5%, or 6% by weight or any fractional amounts, for example, 1.5%, 3,25%, and

5.75%.
The disclosed base compositions can comprise from about 3% to about 20% by weight of sunflower oil. In one embodiment the base compositions can comprise from about 3% to about 15% by weight of sunflower oil. In another embodiment the base compositions can comprise from about 5% to about 17% by weight of sunflower oil. In a further embodiment the base compositions can comprise from about 7.5% to about 15% by weight of sunflower oil.
In a still further embodiment the base compositions can comprise from about 5%
to about 10%
by weight of sunflower oil. For example, the amount of sunflower oil can be 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% by weight of sunflower oil or any fractional amounts, for example, 10.5%, 13.6%, and 17.5%.
According to this aspect the ratio of nicotine, a nicotine salt or nicotine in combination with a resin to sunflower oil is from about 1:1 to about 1:4. For example, the ratio of nicotine, a nicotine salt or nicotine in combination with a resin to sunflower oil can be 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2, 1:2.1, 1:2.2, 1:2.3, 1:2.4, 1:2.5, 1:2.6, 1:2.7, 1:2.8, 1:2.9, or 1:3.
The disclosed base compositions can comprise from about 10% to about 20% by weight of sodium bicarbonate. In one embodiment the base compositions can comprise from about 10% to about 15% by weight of sodium bicarbonate. In another embodiment the base compositions can comprise from about 15% to about 20% by weight of sodium bicarbonate. In a further embodiment the base compositions can comprise from about 12.5% to about 17.5% by weight of sodium bicarbonate. In a still further embodiment the base compositions can comprise from about 14% to about 17% by weight of sodium bicarbonate. For example, the amount of sodium bicarbonate can be 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% by weight of sodium bicarbonate or any fractional amounts, for example, 10.5%, 13.6%, and 17.5%.
In another aspect the base compositions can comprise:
a) from about 5 mg to about 50 mg by weight of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof;
b) from about 15 mg to about 160 mg by weight of sunflower oil; and c) from about 50 mg to about 300 mg by weight of sodium bicarbonate.

ATTORNEY DOCKET NO. 07341.020W01 The disclosed base compositions can comprise from 5 mg to about 50 mg by weight of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof.
In one embodiment the base compositions can comprise from 10 mg to about 50 mg by weight of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof. In another embodiment the base compositions can comprise from 15 mg to about 40 mg by weight of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof. In a further embodiment the base compositions can comprise from 10 mg to about 30 mg by weight of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof. In a still further embodiment the base compositions can comprise from 15 mg to about 30 mg by weight of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof. In a yet further embodiment the base compositions can comprise from 10 mg to about 25 mg by weight of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof. The base compositions can comprise, for example, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, or 50 mg by weight of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof or any fractional amount, for example, 7.5 mg, 22.5 mg, and 34.6 mg.
The disclosed base compositions can comprise from about 15 mg to about 160 mg by weight of sunflower oil. In one embodiment the base compositions can comprise from about 15 mg to about 160 mg by weight of sunflower oil. In another embodiment the base compositions can comprise from about 25 mg to about 120 mg by weight of sunflower oil. In a further embodiment the base compositions can comprise from about 40 mg to about 100 mg by weight of sunflower oil. In a still further embodiment the base compositions can comprise from about 50 mg to about 150 mg by weight of sunflower oil. In a yet further embodiment the base compositions can comprise from about 75 mg to about 120 mg by weight of sunflower oil.
The disclosed base compositions can comprise, for example, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, 70 mg, 71 mg, 72 mg, 73 mg, 74 mg, 75 mg, 76 mg, 77 mg, 78 mg, 79 mg, 80 mg, 81 mg,

6 ATTORNEY DOCKET NO. 07341.020W01 82 mg, 83 mg, 84 mg, 85 mg, 86 mg, 87 mg, 88 mg, 89 mg, 90 mg, 90 mg, 91 mg, 92 mg, 93 mg, 94 mg, 95 mg, 96 mg, 97 mg, 98 mg, 99 mg, 100 mg, 101 mg, 102, mg, 103, mg, 104 mg, 105 mg, 106 mg, 107 mg, 108 mg, 109 mg, 110 mg, 111 mg, 112 mg, 113 mg, 114 mg, 115 mg, 116 mg, 117 mg, 118 mg, 119 mg, 120 mg, 121 mg, 122 mg, 123 mg, 124 mg, 125 mg, 126 mg, 127 mg, 128 mg, 129 mg, 130 mg 31 mg, 132 mg, 133 mg, 134 mg, 135 mg, 136 mg, 137 mg, 138 mg, 139 mg, 140 mg, 141 mg, 142 mg, 143 mg, 144 mg, 145 mg, 146 mg, 147 mg, 148 mg, 149 mg, 150 mg, 151 mg, 152 mg, 153 mg, 154 mg, 155 mg, 156 mg, 157 mg, 158 mg, 159 mg, or 160 mg by weight of sunflower oil or any fractional amount, for example, 27.5 mg, 82.5 mg, and 134.6 mg.
The disclosed base compositions can comprise from about 50 mg to about 300 mg by weight of sodium bicarbonate. In one embodiment the base compositions comprise from about 50 mg to about 100 mg by weight of sodium bicarbonate. In another embodiment the base compositions comprise from about 75 mg to about 100 mg by weight of sodium bicarbonate.
In a further embodiment the base compositions comprise from about 100 mg to about 200 mg by weight of sodium bicarbonate. In still further embodiment the base compositions comprise from about 150 mg to about 200 mg by weight of sodium bicarbonate. In a yet further embodiment the base compositions comprise from about 150 mg to about 300 mg by weight of sodium bicarbonate. In a yet another embodiment the base compositions comprise from about 225 mg to about 300 mg by weight of sodium bicarbonate. The disclosed base composition can comprise, for example, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, 70 mg, 71 mg, 72 mg, 73 mg, 74 mg, 75 mg, 76 mg, 77 mg, 78 mg, 79 mg, 80 mg, 81 mg, 82 mg, 83 mg, 84 mg, 85 mg, 86 mg, 87 mg, 88 mg, 89 mg, 90 mg, 90 mg, 91 mg, 92 mg, 93 mg, 94 mg, 95 mg, 96 mg, 97 mg, 98 mg, 99 mg, 100 mg, 101 mg, 102 mg, 103, mg, 104 mg, 105 mg, 106 mg, 107 mg, 108 mg, 109 mg, 110 mg, 111 mg, 112 mg, 113 mg, 114 mg, 115 mg, 116 mg, 117 mg, 118 mg, 119 mg, 120 mg, 121 mg, 122 mg, 123 mg, 124 mg, 125 mg, 126 mg, 127 mg, 128 mg, 129 mg, 130 mg 31 mg, 132 mg, 133 mg, 134 mg, 135 mg, 136 mg, 137 mg, 138 mg, 139 mg, 140 mg, 141 mg, 142 mg, 143 mg, 144 mg, 145 mg, 146 mg, 147 mg, 148 mg, 149 mg, 150 mg, 151 mg, 152 mg, 153 mg, 154 mg, 155 mg, 156 mg, 157 mg, 158 mg, 159 mg, 160 mg, 161 mg, 162 mg, 163 mg, 164 mg, 165 mg, 166 mg, 167 mg, 168 mg, 169 mg, 170 mg, 171 mg, 172 mg, 173 mg, 174 mg, 175 mg, 167 mg, 177 mg, 178 mg, 179 mg, 180 mg, 181 mg, 182 mg, 183 mg, 184 mg, 185 mg, 186 mg, 187 mg, 188 mg, 189 mg, 190 mg, 191

7 ATTORNEY DOCKET NO. 07341.020W01 mg, 192 mg, 193 mg, 194 mg, 195 mg, 196 mg, 197 mg, 198 mg, 199 mg, 200 mg, 201 mg, 202 mg, 203 mg, 204 mg, 205 mg, 206 mg, 207 mg, 208 mg, 209 mg, 210 mg, 211 mg, 212 mg, 213 mg, 214 mg, 215 mg, 216 mg, 217 mg, 218 mg, 219 mg, 220 mg, 221 mg, 222 mg, 223 mg, 224 mg, 225 mg, 226 mg, 227 mg, 228 mg, 229 mg, 230 mg, 231 mg, 232 mg, 233 mg, 234 mg, 235 mg, 236 mg, 237 mg, 238 mg, 239 mg, 240 mg, 241 mg, 242 mg, 243 mg, 244 mg, 245 mg, 246 mg, 247 mg, 248 mg, 249 mg, 250 mg, 251 mg, 252 mg, 253 mg, 254 mg, 255 mg, 256 mg, 257 mg, 258 mg, 259 mg, 260 mg, 261 mg, 2 62 mg, 263 mg, 264 mg, 265 mg, 266 mg, 267 mg, 268 mg, 269 mg, 270 mg, 271 mg, 272 mg, 273 mg, 274 mg, 275 mg, 276 mg, 277 mg, 278 mg, 279 mg, 280 mg, 281 mg, 282 mg, 283 mg, 284 mg, 285 mg, 286 mg, 287 mg, 288 mg, 289 mg, 290 mg, 290 mg, 291 mg, 292 mg, 293 mg, 294 mg, 295 mg, 296 mg, 297 mg, 298 mg, 299 mg, or 300 mg by weight of sodium bicarbonate, or any fractional amount, for example, 110.5, 220.7 and 250.8.
Nicotine Compounds The disclosed nicotine compounds are chosen from nicotine, pharmacologically acceptable salts of nicotine, a nicotine complexes, and polymer resins of containing nicotine.
Non-limiting examples of nicotine salts includes nicotine benzoate, nicotine lactate, nicotine malate, nicotine ditartrate, nicotine salicylate, nicotine citrate and nicotine levulinate. Non-limiting examples of nicotine in combination with a resin includes nicotine polacrilex and nicotine resinate.
In one non-limiting example the nicotine salt is nicotine benzoate. In another non-limiting example the nicotine salt is nicotine lactate. In a further non-limiting example the nicotine salt is nicotine malate. In a yet further non-limiting example the nicotine salt is nicotine ditartrate. In a still yet further non-limiting example the nicotine salt is nicotine salicylate. In a yet another non-limiting example the nicotine salt is nicotine citrate. In a still yet another non-limiting example the nicotine salt is nicotine levulinate.
Carriers In one aspect the disclosed carriers are polysaccharides. Non-limiting examples of poly saccharide carriers include inulin, galactogen, cellulose, chitin, pectin, psyllium, guar, hemicellulose, potato starch, and partially hydrolyzed polysaccharides. In another aspect the carriers are sugar alcohols, for example, sorbitol, erythritol, xylitol, lactitol, maltitol, mannitol, hydrogenated starch hydrolysates, isomaltose, or any combination thereof In a further aspect carrier component is based on a native or chemically modified agar, alginates, carrageenan

8 ATTORNEY DOCKET NO. 07341.020W01 gum, cellulose, chitosan, chitin, cyclodextrin, dextran, gellan gum, glycogen, glycosaminoglycan, gum karaya, inulin, pectin, polydextrose, xanthan gum, or any other starches, gums or other polysaccharide, including functionalized derivatives, dextfinized, hydrolyzed, oxidized, alkylated, hydroxyalkylated, acetylated, fractionated, and physically modified starches and mixtures thereof. In some embodiments glycerin and/or propylene glycol can be added as a carrier.
In one aspect the carrier can serve as a bulking agent. In one embodiment, microcrystalline cellulose is utilized as a carrier in the base compositions and as a bulking agent in the pouches disclosed herein below. In another embodiment, two or more carriers can be combined, for example, microcrystalline cellulose and inulin. This combination can be utilized in both the base composition, as well as in the pouches. As it relates to the disclosed pouches, dextrin is added as a bulking agent, however, dextrin can also serve as carrier for any flavors that the formulator wishes to add. For example, ethylvanillin is a compound which provides vanilla flavoring. Ethylvanillin can be compounded with dextrin, microcrystalline cellulose or inulin and then admixed with the bulking agents or other carriers.
In one aspect of the one or more carriers, one of the carriers is water soluble while others are not. This allows the formulator to control the release of the active base when the active base is delivered by way of a non-water soluble, but water permeable pouch as described herein below. This combining of carriers allows the delivery of nicotine either via a nicotine salt or by way of a polymer supported nicotine, for example, polacrilex.
The disclosed compositions can comprise from about 80% to about 95% by weight of one or more carriers. In one embodiment the disclosed compositions can comprise from about 80% to about 90% by weight of one or more carriers. In another embodiment the disclosed compositions can comprise from about 85% to about 95% by weight of one or more carriers.
In a further embodiment the disclosed compositions can comprise from about 85%
to about 90% by weight of one or more carriers.
Antioxidants The disclosed compositions can comprise about 0.05% or less of an antioxidant.
Non-limiting examples of an antioxidant includes butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate (PG), tert-butyl hydroquinone (TBHQ), and mixtures thereof.

9 ATTORNEY DOCKET NO. 07341.020W01 The following tables disclose non-limiting examples of the base nicotine delivery compositions.

Ingredients (mg) 1 2 3 4 5 Nicotine benzoate 5 17.5 7.5 15 17.5 Sunflower oil 15 52.5 22.5 45 35 Sodium bicarbonate 50 100 100 100 Inulin LV 110 430 660 370 340 347.5 Total 500 500 500 500 Ingredients (mg) 6 7 8 9 10 Nicotine benzoate 12.5 17.5 5 10 7.5 Sunflower oil 25 52.5 15 30 22.5 Sodium bicarbonate 75 75 100 100 Inulin LV 110 387.5 355 380 360 Total 500 500 500 500 Ingredients (mg) 11 12 13 14 15 Nicotine benzoate 10 35 15 30 35 Sunflower oil 30 105 45 90 70 Sodium bicarbonate 100 200 200 200 Inulin LV 110 860 660 740 680 Total 1000 1000 1000 1000 ATTORNEY DOCKET NO. 07341.020W01 Ingredients (mg) 16 17 18 19 20 Nicotine benzoate 25 35 10 20 15 Sunflower oil 50 105 30 60 45 Sodium bicarbonate 150 150 200 200 Inulin LV 110 775 710 760 720 Total 1000 1000 1000 1000 Ingredients (mg) 21 22 23 24 25 Nicotine benzoate 15 52.5 22.5 45 52.5 Sunflower oil 45 157.5 67.5 135 Sodium bicarbonate 150 300 300 300 Inulin LV 110 1290 990 1110 1020 1042.5 Total 1500 1500 1500 1500 Ingredients (mg) 26 27 28 29 30 Nicotine benzoate 37.5 52.5 15 30 22.5 Sunflower oil 75 157.5 45 90 67.5 Sodium bicarbonate 225 225 300 300 Inulin LV 110 1162.5 1065 1140 1080 Total 1500 1500 1500 1500 Ingredients (mg) 31 32 33 34 35 Nicotine polacrilex 5 17.5 7.5 15 17.5 Sunflower oil 15 52.5 22.5 45 35 Sodium bicarbonate 50 100 100 100 Inulin LV 110 430 660 370 340 347.5 Total 500 500 500 500 ATTORNEY DOCKET NO. 07341.020W01 Ingredients (mg) 36 37 38 39 40 Nicotine polacrilex 12.5 17.5 5 10 7.5 Sunflower oil 25 52.5 15 30 22.5 Sodium bicarbonate 75 75 100 100 Inulin LV 110 387.5 355 380 360 Total 500 500 500 500 Ingredients (mg) 41 42 43 44 45 Nicotine polacrilex 10 35 15 30 35 Sunflower oil 30 105 45 90 70 Sodium bicarbonate 100 200 200 200 Inulin LV 110 860 660 740 680 Total 1000 1000 1000 1000 Ingredients (mg) 46 47 48 49 50 Nicotine polacrilex 25 35 10 20 15 Sunflower oil 50 105 30 60 45 Sodium bicarbonate 150 150 200 200 Inulin LV 110 775 710 760 720 Total 1000 1000 1000 1000 Ingredients (mg) 51 52 53 54 55 Nicotine polacrilex 15 52.5 22.5 45 52.5 Sunflower oil 45 157.5 67.5 135 Sodium bicarbonate 150 300 300 300 Inulin LV 110 1290 990 1110 1020 1042.5 Total 1500 1500 1500 1500 ATTORNEY DOCKET NO. 07341.020W01 Ingredients (mg) 56 57 58 59 50 Nicotine polacrilex 37.5 52.5 15 30 22.5 Sunflower oil 75 157.5 45 90 67.5 Sodium bicarbonate 225 225 300 300 Inulin LV 110 1162.5 1065 1140 1080 Total 1500 1500 1500 1500 KITS
Disclosed herein are kits for sublingual delivery of nicotine. The kits contain a base nicotine delivery system which comprises the active ingredients and a non-water soluble liquid permeable pouch into which the active ingredients and any necessary adjunct ingredients useful for delivery of the nicotine, nicotine salt of nicotine resin compositions. In one aspect the kit comprises a pouch containing a disclosed composition, comprising:
A) a liquid permeable pouch comprising a non-nicotine composition comprising:
a) one or more delivery agents; and b) a bulking agent; and B) a base nicotine delivery composition comprising:
a) nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof;
b) sunflower oil;
c) sodium bicarbonate; and d) the balance one or more carriers.
Delivery Control Agents In order to control sublingual delivery of the disclosed nicotine-containing compositions the kits contain one or more agents that control the release of nicotine into the mouth of the use.
These agents are typically formulated after assembly of the base nicotine delivery compositions; however, the formulator can add a delivery control agent as part of a carrier system.
In one embodiment the delivery agents are solubilizers, for example, lecithins, polyoxyethylene stearate, polyoxyethylene sorbitan fatty acid esters, fatty acid salts, mono and ATTORNEY DOCKET NO. 07341.020W01 diacetyl tartaric acid esters of mono and diglycerides of edible fatty acids, citric acid esters of mono and diglycerides of edible fatty acids, saccharose esters of fatty acids, polyglycerol esters of fatty acids, polyglycerol esters of interesterified castor oil acid (E476), sodium stearoyl lactylate, sodium lauryl sulfate and sorbitan esters of fatty acids and polyoxyethylated hydrogenated castor oil (for example, CREMOPHORTm), block copolymers of ethylene oxide and propylene oxide (for example, one or more PLURONICSTM or POLOXAMERSTm), polyoxyethylene fatty alcohol ethers, polyoxyethylene sorbitan fatty acid esters, sorbitan esters of fatty acids and polyoxyethylene stearic acid esters.
In one embodiment the delivery agent is chosen from sodium stearoyl lactylate, sodium lauryl sulfate, glycerol, propylene glycol, b-cyclodextrin and propylene glycol 400 (PEG 400).
Non-limiting examples of solubilizers includes glycerol, propylene glycol, b-cyclodextrin and propylene glycol 400 (PEG 400).
In one aspect of the disclosed kits, the kits comprise:
A) a liquid permeable pouch comprising a non-nicotine composition comprising:
a) one or more delivery agents; and b) a bulking agent; and B) a base nicotine delivery composition comprising:
a) nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof;
b) sunflower oil;
c) sodium bicarbonate; and d) the balance one or more carriers.
In one embodiment of this aspect, the kits comprise:
A) a liquid permeable pouch comprising a non-nicotine composition comprising:
a) one or more delivery agents; and b) a bulking agent; and B) a base nicotine delivery composition comprising:
a) from about 1% to about 6% by weight of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof;
b) from about 3% to about 20% by weight of sunflower oil;
c) from about 10% to about 20% by weight of sodium bicarbonate; and d) the balance one or more carriers.

ATTORNEY DOCKET NO. 07341.020W01 In one iteration of this embodiment, the kits comprise:
A) a liquid permeable pouch comprising a non-nicotine composition comprising:
a) maltitol; and b) an admixture of microcrystalline cellulose and inulin; and B) a base nicotine delivery composition comprising:
a) from about 1% to about 6% by weight of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof;
b) from about 3% to about 20% by weight of sunflower oil;
c) from about 10% to about 20% by weight of sodium bicarbonate; and d) the balance:
i) dextrose; and ii) a flavorant.
Non-limiting examples of flavorants include apple, banana, cherry, cinnamon, grape, orange, pear, pineapple, raspberry, blueberry, strawberry, spearmint, peppermint, wintergreen, and vanilla.
Disclosed herein is a kit, comprising:
A) a liquid permeable pouch comprising a non-nicotine composition comprising:
a) one or more delivery control agents; and b) a bulking agent; and B) a base nicotine delivery composition comprising:
a) nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof;
b) sunflower oil;
c) sodium bicarbonate; and d) the balance one or more carriers.
In one non-limiting example, the kit comprises:
A) a liquid permeable pouch comprising a non-nicotine composition comprising:
a) one or more delivery control agents; and b) a bulking agent; and B) from about 70 mg to about 510 mg of an active base delivery system, comprising:
a) from about 5 mg to about 50 mg by weight of nicotine benzoate;

ATTORNEY DOCKET NO. 07341.020W01 b) from about 15 mg to about 160 mg by weight of sunflower oil;
c) from about 50 mg to about 300 mg by weight of sodium bicarbonate;
d) from about 350 mg to about 1500 mg of one or more carriers; and e) the balance one or more delivery control agents.
In another non-limiting example, the kit comprises:
A) a liquid permeable pouch comprising a non-nicotine composition comprising:
a) one or more delivery control agents; and b) a bulking agent; and B) from about 70 mg to about 510 mg of an active base delivery system, comprising:
a) from about 5 mg to about 50 mg by weight of nicotine polacrilex;
b) from about 15 mg to about 160 mg by weight of sunflower oil;
c) from about 50 mg to about 300 mg by weight of sodium bicarbonate;
d) from about 350 mg to about 1500 mg of one or more carriers; and e) the balance one or more delivery control agents.
PREPARATION
The disclosed base compositions can be prepared by the following general procedure.
Nicotine, a nicotine salt, or nicotine in combination with a resin, is combined with sunflower oil in a vessel with adequate stirring. The amount of each ingredient varies depending upon the formulator's choice of the ratio of the nicotine-containing ingredient and sunflower oil, i.e., the ratio of nicotine-containing ingredient to sunflower oil can be, as disclosed herein above, from about 1:1 to about 1:3. The choice of ratio will also dictate the relative amounts of adjunct ingredients that are added. With stirring, the nicotine-containing ingredient sunflower oil admixture is then slowly heated to from about 50 C to about 75 C, again predicated on the ratio of ingredients and the choice of excipients.
At this point antioxidants, as well as other adjunct ingredients can be optionally added to the nicotine-containing compound/sunflower oil admixture during heating.
The amount and ratio of any antioxidants added to the admixture varies depending upon the formulator's choice.
In one non-limiting embodiment, the amount of antioxidant is from about 0.01%
to about 0.10% by weight of the admixture.
Following the optional addition of an antioxidant and/or other adjunct ingredients, the resulting admixture is then slowly added to a dry particulate substrate with sufficient mixing to ATTORNEY DOCKET NO. 07341.020W01 form a homogenous dispersion. The quantity of the admixture that is added to the substrate is from about 5% to about 60% by weight. The final dispersion is then dehydrated by which ever means chosen by the formulator, for example, oven drying, lyophilization, convection drying, microwave radiation, etc. In one non-limiting embodiment, the dispersion is dried from about 45 to about 135 minutes. Depending upon many factors including the type of adjunct ingredients and the ratio of the nicotine-containing compound to sunflower oil, the time can be shortened or lengthened.
At this point an alkalizing agent is incorporated. In one non-limiting example, sodium bicarbonate is used as the alkalizing agent. The amount of alkalizing agent is predicated on the amounts of other ingredients and the choice of substrate. In one non-limiting embodiment the composition can comprise from about 1% to about 25% by weight of the alkalizing agent.
After homogenizing the alkalizing agent into the homogeneous admixture now formed, other adjunct ingredients can be added. Non-limiting examples include bulking agents which provide a mouthfeel that is compatible with the pouches, thereby providing the user with a feeling of "substance" inside the pouch. Bulking agents include microcrystalline cellulose and inulin. In addition, sweeteners, for example, maltitol, and/or flavoring compounds are added to provide different oral sensations.
The resulting composition can then be further compounded with other adjunct ingredients, at levels that vary depending upon the formulator's choice, such as bulking agents (e.g., microcrystalline cellulose), high potency sweeteners (e.g., maltitol) and/or flavoring compounds, and ultimately rendered in various different oral or intraoral form factors.
In one non-limiting example, nicotine benzoate (15 g) and sunflower oil (45 g) are combined in a stainless-steel reaction vessel with efficient stirring and heated to 50 C until homogeneous. The nicotine benzoate sunflower oil admixture is then slowly metered into inulin (500 g) as a dry particulate substrate compound while mixing until homogeneously dispersed. Sodium bicarbonate (20 g) is added while mixing until homogenously dispersed.
The admixture is then placed in a convection airflow dehydration chamber for 90 minutes to remove remaining moisture and effect a molecular association between the nicotine and the sunflower oil infused dry particulate. The resulting composition is then combined with microcrystalline cellulose (200 g), maltitol (175 g) and spearmint flavoring (100 g) and then charged to unit dose oral pouches.
Pouches ATTORNEY DOCKET NO. 07341.020W01 The properties of the pouch can influence the release of the nicotine, nicotine salt, or nicotine in combination with a resin from the pouch composition and thereby possibly influence the rate of uptake by the user. The disclosed pouches comprise water insoluble fiber which allows moisture, typically the user's saliva, to enter the pouch and solubilize the water-soluble components.
Disclosed herein are water-insoluble pouches which can comprise insoluble fiber, for example, wheat fibers, oat fibers, pea fibers, rice fiber, maize fibers, oat fibers, tomato fibers, barley fibers, rye fibers, sugar beet fibers, buckwheat fibers, potato fibers, cellulose fibers, apple fibers, cocoa fibers, cellulose fiber, powdered cellulose, bamboo fibers, bran fibers or combinations thereof.
In one embodiment the disclosed pouches comprise cellulose prepared by processing alpha-cellulose obtained as a pulp from strains of fibrous plant materials, such as wood pulp.
In a further embodiment the pouches can comprise wheat fibers, oat fibers, or combinations thereof.
The following are non-limiting examples of plant fibers Vitacel WF 600TM, Vitacel HF
600TM, Vitacel P95Tm, Vitacel WF 200TM, Vitacel LOOTM, Vitacel Erbsenfaser EF
150 TM, Vitacel bamboo fiberbaf 90TM, Vitacel HF 600TM, Vitacel Cellulose L700GTM, Vitacel PF200TM, Vitacel potatofiber KF200TM Vitacel bamboo fiberhaf BAF40Tm, Vitacel Haferfaser/oat fiber HF-401-30Tm, Vitacel L 00TM, Vitacel Cellulose L700GTM, Vitacel LC1000TM, Vitacel L60020TM, Vitacel L600TM or combination thereof In formulating pouches containing various amounts of the base nicotine delivery composition it is one embodiment of the present disclosure that the amount of water-insoluble fiber can be reduced without compromising the mouthfeel during use. It is important that the pouch material does not cause swelling in use because this fact can counteract the dissolution of the water-soluble component, thereby preventing the user from experiencing any decrease in pouch content during use.
In addition, the pouch composition can also provide for a desirable mouthfeel such as a soft and/or sticky texture. The desirable texture and mouthfeel can be obtained while still being able to store manufactured pouches together in abutment, for example, in cans and the like without sticking or clumping together to result in ruptures of the pouches when being removed.
The desirable mouthfeel can in some embodiments also comprise a tingling sensation ATTORNEY DOCKET NO. 07341.020W01 reminiscent of tobacco pouches, but without many of the undesirable effects associated therewith, for example, discoloring of tissue.
In one aspect of the disclosed kits, the kits comprise an active base composition and a pouch for delivery of nicotine sublingually to the user.
The kits comprise a water-permeable pouch, into which an active base composition and a delivery system is added. The disclosed pouches comprise:
A) from about 5% to about 20% by weight of an active base composition, comprising"
a) from about 1% to about 6% by weight of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof;
b) from about 3% to about 20% by weight of sunflower oil;
c) from about 10% to about 20% by weight of sodium bicarbonate; and B) from about 80% to about 95% by weight of a delivery system wherein the delivery control system contains one or more delivery control agents, carriers, solubilizers or mixtures thereof.
In one embodiment of this aspect, the pouches comprise:
A) from about 70 mg to about 510 mg of an active base composition, comprising:
a) from about 5 mg to about 50 mg by weight of nicotine benzoate;
b) from about 15 mg to about 160 mg by weight of sunflower oil;
c) from about 50 mg to about 300 mg by weight of sodium bicarbonate;
B) from about 350 mg to about 1500 mg of one or more carriers; and C) the balance one or more delivery control agents.
In one iteration of this embodiment, the one or more carriers serves as the delivery control agent. For example, a pouch comprising:
a) from about 5 mg to about 50 mg by weight of nicotine benzoate;
b) from about 15 mg to about 160 mg by weight of sunflower oil;
c) from about 50 mg to about 300 mg by weight of sodium bicarbonate; and d) from about 300 mg to about 1300 mg by weight of a carrier chosen from inulin, galactogen, cellulose, chitin, pectin, psyllium, guar, hemicellulose, potato starch, or partially hydrolyzed polysaccharides.
In another iteration of this embodiment, a pouch comprising:
a) from about 5 mg to about 50 mg by weight of nicotine benzoate;

ATTORNEY DOCKET NO. 07341.020W01 b) from about 15 mg to about 160 mg by weight of sunflower oil;
c) from about 50 mg to about 300 mg by weight of sodium bicarbonate; and d) from about 300 mg to about 1300 mg by weight of a carrier chosen from, sorbitol, erythtitol, xylitol, lactitol, maltitol, mannitol, hydrogenated starch hydrolysates, isomaltose, or any combination thereof In a still further iteration of this embodiment, a pouch comprising:
a) from about 5 mg to about 50 mg by weight of nicotine benzoate;
b) from about 15 mg to about 160 mg by weight of sunflower oil;
c) from about 50 mg to about 300 mg by weight of sodium bicarbonate; and d) from about 300 mg to about 1300 mg by weight of inulin.
In a yet still further iteration of this embodiment, a pouch comprising:
a) from about 5 mg to about 50 mg by weight of nicotine benzoate;
b) from about 15 mg to about 160 mg by weight of sunflower oil;
c) from about 50 mg to about 300 mg by weight of sodium bicarbonate; and d) from about 300 mg to about 1300 mg by weight of microcrystalline cellulose.
In a yet still further iteration of this embodiment, a pouch comprising:
a) from about 5 mg to about 50 mg by weight of nicotine benzoat;
b) from about 15 mg to about 160 mg by weight of sunflower oil;
c) from about 50 mg to about 300 mg by weight of sodium bicarbonate; and d) from about 300 mg to about 1300 mg by weight of an admixture of inulin and microcrystalline cellulose.
In another embodiment of this aspect, the pouches comprise:
A) from about 70 mg to about 510 mg of an active base composition, comprising:
a) from about 5 mg to about 50 mg by weight of nicotine polacrilex;
b) from about 15 mg to about 160 mg by weight of sunflower oil;
c) from about 50 mg to about 300 mg by weight of sodium bicarbonate;
B) from about 350 mg to about 1500 mg of one or more carriers; and C) the balance one or more delivery control agents.
In one iteration of this embodiment, the one or more carriers serves as the delivery control agent. For example, a pouch comprising:
a) from about 5 mg to about 50 mg by weight of nicotine polacrilex;
b) from about 15 mg to about 160 mg by weight of sunflower oil;

ATTORNEY DOCKET NO. 07341.020W01 c) from about 50 mg to about 300 mg by weight of sodium bicarbonate; and d) from about 300 mg to about 1300 mg by weight of a carrier chosen from inulin, galactogen, cellulose, chitin, pectin, psyllium, guar, hemicellulose, potato starch, or partially hydrolyzed polysaccharides.
In another iteration of this embodiment, a pouch comprising:
a) from about 5 mg to about 50 mg by weight of nicotine polacrilex;
b) from about 15 mg to about 160 mg by weight of sunflower oil;
c) from about 50 mg to about 300 mg by weight of sodium bicarbonate; and d) from about 300 mg to about 1300 mg by weight of a carrier chosen from, sorbitol, erythtitol, xylitol, lactitol, maltitol, mannitol, hydrogenated starch hydrolysates, isomaltose, or any combination thereof.
In a still further iteration of this embodiment, a pouch comprising:
a) from about 5 mg to about 50 mg by weight of nicotine polacrilex;
b) from about 15 mg to about 160 mg by weight of sunflower oil;
c) from about 50 mg to about 300 mg by weight of sodium bicarbonate; and d) from about 300 mg to about 1300 mg by weight of inulin.
In a yet still further iteration of this embodiment, a pouch comprising:
a) from about 5 mg to about 50 mg by weight of nicotine polacrilex;
b) from about 15 mg to about 160 mg by weight of sunflower oil;
c) from about 50 mg to about 300 mg by weight of sodium bicarbonate; and d) from about 300 mg to about 1300 mg by weight of microcrystalline cellulose.
In a yet still further iteration of this embodiment, a pouch comprising:
a) from about 5 mg to about 50 mg by weight of nicotine polacrilex;
b) from about 15 mg to about 160 mg by weight of sunflower oil;
c) from about 50 mg to about 300 mg by weight of sodium bicarbonate; and d) from about 300 mg to about 1300 mg by weight of an admixture of inulin and microcrystalline cellulose.
The disclosed compositions can comprise from about 80% to about 95% by weight of one or more delivery control agents, carriers, solubilizers or mixtures thereof In one embodiment the disclosed compositions can comprise from about 80% to about 90%
by weight of one or more delivery control agents, carriers, solubilizers or mixtures thereof In another embodiment the disclosed compositions can comprise from about 85% to about 95%
by weight ATTORNEY DOCKET NO. 07341.020W01 of one or more delivery control agents, carriers, solubilizers or mixtures thereof. In a further embodiment the disclosed compositions can comprise from about 85% to about 90%
by weight of one or more delivery control agents, carriers, solubilizers or mixtures thereof.
PROCESS
The disclosed base compositions can be prepared by the following general procedure.
Nicotine, a nicotine salt, or nicotine in combination with a resin, is combined with sunflower oil in a vessel with adequate stirring. The amount of each ingredient varies depending upon the formulator's choice of the ratio of the nicotine-containing ingredient and sunflower oil, i.e., the ratio of nicotine-containing ingredient to sunflower oil is from about 1:1 to about 1:3. The choice of ratio will also dictate the relative amounts of adjunct ingredients that are added. With stirring, the nicotine-containing ingredient sunflower oil admixture is then slowly heated to from about 50 C to about 75 C, again predicated on the ratio of ingredients and the choice of excipients.
In one non-limiting example, nicotine benzoate (15 g) and sunflower oil (45 g) are combined in a stainless-steel reaction vessel with efficient stirring and heated to 50 C until homogeneous. Inulin (500 g) is slowly metered in and stirring continued until all the inulin is dispersed. Sodium bicarbonate (150 g) is slowly added while raising the temperature to 60 C.
Once the admixture is homogeneous, inulin (790 g) is added at a rate to maintain a homogeneous admixture. The admixture is then slowly cooled to 30 C and placed in a vacuum oven for 5 hours to remove all of the remaining moisture. The resulting composition can then be combined with additional inulin or microcrystalline cellulose then charged to one or more pouches.
The following are non-limiting examples of compositions delivered by way of an insoluble plant or synthetic pouch.

ATTORNEY DOCKET NO. 07341.020W01 Ingredients (mg) A B C D E
Nicotine benzoate 5 17.5 7.5 15 17.5 Sunflower oil 15 52.5 22.5 45 35 Sodium bicarbonate 50 100 100 100 Inulin LV 110 300 460 170 240 147.5 0-cyc1odextrin 130 200 200 100 Total 500 500 500 500 Ingredients (mg) F G II I J
Nicotine benzoate 5 17.5 7.5 15 17.5 Sunflower oil 15 52.5 22.5 45 35 Sodium bicarbonate 50 100 100 100 Inulin LV 110 330 510 210 240 247.5 propylene glycol 100 150 80 100 Total 500 500 500 500 Ingredients (mg) K L M N 0 Nicotine benzoate 5 17.5 7.5 15 17.5 Sunflower oil 15 52.5 22.5 45 35 Sodium bicarbonate 50 100 100 100 Inulin LV 110 320 510 270 240 197.5 glycerol 110 150 100 100 Total 500 500 500 500 ATTORNEY DOCKET NO. 07341.020W01 Ingredients (mg) P Q R S T
Nicotine benzoate 5 17.5 7.5 15 17.5 Sunflower oil 15 52.5 22.5 45 35 Sodium bicarbonate 50 100 100 100 Inulin LV 110 330 560 190 240 247.5 Total 500 500 500 500 Ingredients (mg) U V W X Y
Nicotine polacrilex 5 17.5 7.5 15 17.5 Sunflower oil 15 52.5 22.5 45 35 Sodium bicarbonate 50 100 100 100 Inulin LV 110 300 460 170 240 147.5 p-cyclodextrin 130 200 200 100 Total 500 500 500 500 Ingredients (mg) Z AA BB CC
DD
Nicotine polacrilex 5 17.5 7.5 15 17.5 Sunflower oil 15 52.5 22.5 45 35 Sodium bicarbonate 50 100 100 100 Inulin LV 110 330 510 210 240 247.5 propylene glycol 100 150 80 100 Total 500 500 500 500 ATTORNEY DOCKET NO. 07341.020W01 Ingredients (mg) EE FF GG 1111 II
Nicotine polacrilex 5 17.5 7.5 15 17.5 Sunflower oil 15 52.5 22.5 45 35 Sodium bicarbonate 50 100 100 100 Inulin LV 110 320 510 270 240 197.5 glycerol 110 150 100 100 Total 500 500 500 500 Ingredients (mg) JJ KK LL MM
NN
Nicotine polacrilex 5 17.5 7.5 15 17.5 Sunflower oil 15 52.5 22.5 45 35 Sodium bicarbonate 50 100 100 100 Inulin LV 110 330 560 190 240 247.5 Total 500 500 500 500 As demonstrated by the following data and Figures 1 to 8, the disclosed compositions are more effective in increasing the plasma level of nicotine via oral delivery than providing nicotine alone in a carrier. The following animal study provides conclusive proof of this fact.
The disclosed animal studies were conducted utilizing the disclosed compositions.
Table I summarizes the Study design. Male Beagle dogs from Marshall Bioresources were utilized for this study. Animals were identified by ear tattoo and cage label.
The study was not blinded. The animals were healthy at the start of the study. Body weights were recorded at each dosing time point. General health observations were recorded at each dosing and sample collection time point for the duration of the study.
Dosing Nicotine, 4 mg per pouch, was administered via buccal administration. Animals were anesthetized with propofol at a dose of 6 mg/kg, animals were then intubated and maintained in an anesthetic state using isoflurane at 1-5% and 2 L of oxygen flow. The pouch with test article was placed in the buccal space, rinsed with a small volume of water (0.5 - lmL). Every ATTORNEY DOCKET NO. 07341.020W01 minutes after placing the pouch the test article test article in the buccal space, the isoflurane mask was removed and the pouch gently squeezed. Special attention was taken to ensure saliva did not leak from the mouth. Following 30 minutes, the pouch test article was removed from the buccal space and the animal allowed to recover from anesthesia. All pouches were retained 5 following dosing. Each pouch was placed in individual conical tube with the animal ID and pouch identification.
TEST COMPOSITIONS
Nicotine Benzoate Control TABLE I
Ingredients % mg Nicotine benzoate 1.11 7 Inulin LV 110 (pre-tested) 98.89 624 Total 100 631 Nicotine Benzoate Disclosed Composition TABLE II
Ingredients % mg Nicotine benzoate 1.37 8.6 Sunflower oil 4.09 25.8 Sodium bicarbonate 13.72 86.6 Inulin LV 110 (pre-tested) 80.82 510 Total 100 631 Nicotine Polacrilex Control TABLE III
Ingredients % mg Nicotine polacrilex 3.6 20 Glycerin 0.4 2.2 Inulin LV 110 (pre-tested) 96.0 632.8 Total 100 555 ATTORNEY DOCKET NO. 07341.020W01 Nicotine Polacrilex Disclosed Composition TABLE IV
Ingredients % mg Nicotine polacrilex 3.91 21.7 Sunflower oil 13.04 72.6 Sodium bicarbonate 13.69 76.1 Glycerin 0.44 2.4 Inulin LV 110 (pre-tested) 68.92 383.2 Total 100 556 As shown in the table below, Group 1 was administered the nicotine benzoate control group. Group 2 was administered the disclosed composition comprising nicotine benzoate.
Group 3 was administered the nicotine polacrilex control. Group 4 was administered the disclose composition comprising nicotine polacrilex. The actual amounts based on results of potency testing was 3.12, 3.31, 3.48, and 3.79 mg per pouch, in Groups 1, 2,3, and 4, respectively TABLE V
Group # Test Dosing N= Dose Dose Blood Article Route (mg/pouch) Volume Sampling Time Points 1 Nicotine benzoate Buccal 10 631 N/A
(Control) 2 Nicotine benzoate Buccal 10 631 N/A
Pre-dose, 2, 4, 6, 8,10, 15, 30, 45, 3 Nicotine polacrilex Buccal 10 555 N/A
60, and 120 (Control) minutespost dose*
4 Nicotine polacrilex Buccal 10 556 N/A
Sample Collection, Preparation and Storage Each blood sample (approx. 2000 L) was collected from the jugular vein in a collection tube and gently inverted several time to mix. The samples were kept on ice until ATTORNEY DOCKET NO. 07341.020W01 centrifugation at 4 C for 5 minutes at 3,000 x g. Approximately 1000 RL plasma was separated by centrifugation. The resulting plasma samples were stored at -80 C until bioanalysis was conducted.
Quantitative Plasma Sample Analysis Plasma samples were extracted by protein precipitation and analyzed using LC-MS/MS.
Individual and Mean plasma concentrations and resulting pharmacokinetic parameters for nicotine are shown in Tables 4 - 7. All data are expressed as ng/mL of nicotine. Samples that were below the limit of quantification (1.0 ng/mL in plasma) were excluded from the calculation of mean values. Mean concentrations versus time data are plotted in Figures 1 - 8.
Pharmacokinetic parameters were calculated from the time course of the plasma concentration. Pharmacokinetic parameters were determined with Phoenix WinNonlin (v8.0) software using a noncompartmental model. The maximum plasma concentration (Cmax) and the time to reach maximum plasma concentration (tmax) after dosing were observed from the data. The area under the time concentration curve (AUC) was calculated using the linear trapezoidal rule with calculation to the last quantifiable data point (AUCO-last), and with extrapolation to infinity (AUCoo) if applicable. Plasma half-life (t1/2) was calculated from 0.693/slope of the terminal elimination phase. Mean residence time, MRT, was calculated by dividing the area under the moment curve (AUMC) by the AUC. Any samples below the limit of quantitation (1.0 ng/mL plasma) were not used in the calculation of mean values DATA
Pharmacokinetic Parameters and Plasma Concentrations (ng/mL) for Nicotine after Buccal Administration of the Nicotine Benzoate Control composition disclosed in TABLES VI and VII in Male Beagle dogs (Group 1) TABLE VI
Animal number Sample time (hr) 1 2 3 4 5 0.0333 15.1 7.43 4.83 5.09 2.39 0.0666 18.7 24.9 46.4 9.37 9.00 0.1 19.3 27.0 50.0 9.5 13.7 0.122 21.5 30.7 301 20.5 19.6 0.167 94.1 32.1 54.3 50.3 20.0 ATTORNEY DOCKET NO. 07341.020W01 Animal number Sample time (hr) 1 2 3 4 5 0.25 50.6 34.0 55.4 192.4 25.4 0.5 50.9 42.6 55.9 88.9 62.8 0.75 49.1 121 94.2 47.4 46.9 1 73.3 49.8 33.9 41.1 38.6 2 12.8 7.05 5.4 12.1 9.17 Dose (mg/kg) 0.354 0.62 0.362 0.385 0.3 Cmax (ng/mL) 94.1 121 94.2 192.4 62.8 tmax (hr) 0.167 0.75 0.75 0.250 0.5 t1/2 0.547 ND2 ND2 0.614 0.516 MRTiast (hr) 0.827 0.792 0.691 0.65 0.815 AUCiast (hr.ng/mL) 93.6 86.1 78.9 102.3 63.0 AUCco(hr.ng/mL) 104 ND2 ND2 113 69.9 AUCiast/D

(hr.kg.ng/mL/mg) AUCco/D

(hr.kg.ng/mL/mg) 1. AUCiast/D (hr.kg.ng/mL/mg) and AUC./D (hr.kg.ng/mL/mg) are dose normalized values.
2. Not determined because the line defining the terminal elimination phase had an r2 of <0.85.
TABLE VII
Animal number Sample time (hr) 6 7 8 9 10 0.0333 15.4 4.45 11.2 BLOQ3 9.41 0.0666 17.0 10.0 181 2.32 38.5 0.1 21.3 21.3 33.2 6.8 40.6 0.122 31.4 28.4 34.0 16.4 0.167 33.4 29.0 34.9 35.3 53.7 ATTORNEY DOCKET NO. 07341.020W01 Animal number Sample time (hr) 6 7 8 9 10 0.25 34.1 43.1 38.6 49.2 50.1 0.5 53.4 67.0 73.2 116.5 55.6 0.75 90.5 44.1 99.4 126.7 57.8 1 57.2 36.2 39.5 37.8 62.8 2 10.5 3.46 5.53 9.6 12.4 Dose (mg/kg) 0.376 0.30 0.416 0.243 0.223 Cmax (ng/mL) 90.5 67.0 99.4 127 62.8 tmax (hr) 0.75 0.50 0.75 0.75 1.0 t1/2 ND2 0.326 ND2 ND2 ND2 MRTiast (hr) 0.822 0.712 0.732 0.738 0.507 AUCiast (hr.ng/mL) 87.4 63.1 82.5 100 89.9 AUCco(hr.ng/mL) ND2 64.7 ND2 ND2 ND2 AUCiast/D

(hr.kg.ng/mL/mg) AUCco/D

(hr.kg.ng/mL/mg) 1. AUCiast/D (hr.kg.ng/mL/mg) and AUC./D (hr.kg.ng/mL/mg) are dose normalized values.9.
2. Not determined because the line defining the terminal elimination phase had an r2 of <0.85.
3. BLOQ = below the limit of quantitation (1 ng/mL) TABLE VIII provides the mean and standard deviation for the results of Animals 1-10.
TABLE VIII
Sample time (hr) mean SD
0.0333 8.36 4.73 0.0666 19.6 14.7 0.1 24.3 13.7 0.122 25.3 6.55 ATTORNEY DOCKET NO. 07341.020W01 Sample time (hr) mean SD
0.167 43.7 21.0 0.25 57.3 48.4 0.5 66.7 24.8 0.75 77.7 32.3 1 47.0 13.3 2 8.79 3.28 Dose (mg/kg) 0.332 0.063 Cmax (ng/mL) 101 39.0 tmax (hr) 0.617 0.258 t1/2 0.501 0.123 MRTIast (hr) 0.759 0.062 AUCiast (hr.ng/mL) 84.7 13.5 AUC.(hr.ng/mL) 87.8 24.1 AUCiasi/D
265 78.3 (hr.kg.ng/mL/mg) AUCco/D
259 40.3 (hr.kg.ng/mL/mg) Figure 1 is a plot of the individual plasma concentrations (ng/mL) for Nicotine versus time (hour) after buccal administration of the nicotine benzoate control composition disclosed in TABLE I in male Beagle dogs. Figure 2 is a plot of the mean plasma concentration (ng/mL) for Nicotine versus time (hour) after buccal administration of nicotine benzoate control composition disclosed in TABLE I in male Beagle dogs.
Pharmacokinetic Parameters and Plasma Concentrations (ng/mL) for Nicotine after Buccal Administration of pouches containing the nicotine benzoate disclosed composition in TABLES IX and X (4 mg) in Male Beagle dogs (Group 2) TABLE IX
Animal number Sample time (hr) 11 12 13 14 15 0.0333 132 50.0 25.6 38.8 107 ATTORNEY DOCKET NO. 07341.020W01 Animal number Sample time (hr) 11 12 13 14 15 0.0666 233 70.9 64.3 332 134 0.1 240 100 78.9 446 412 0.122 247 105 88.7 349 413 0.167 253 117 98.8 258 136 0.25 350 486 113 241 418 0.5 342 175 228 240 647 0.75 150 95.7 91.8 220 153 1 88.2 6104 78.1 83.3 82.4 2 33.0 30.9 21.8 37.0 32.4 Dose (mg/kg) 0.38 0.269 0.331 0.429 0.413 Cmax (ng/mL) 350 486 228 446 647 tmax (hr) 0.25 0.25 0.5 0.10 0.50 t1/2 0.606 0.823 0.583 0.554 0.601 MRTiast (hr) 0.603 0.597 0.710 0.632 0.55 AUCiast (hr.ng/mL) 296 220 173 280 0397 AUCco(hr.ng/mL) 325 257 191 309 425 AUCiast/D

(hr.kg.ng/mL/mg) AUCco/D

(hr.kg.ng/mL/mg) 1. AUCiast/D (hr.kg.ng/mL/mg) and AUC./D (hr.kg.ng/mL/mg) are dose normalized values.
2. Not determined because the line defining the terminal elimination phase had an r2 of <0.85.
TABLE X
Animal number Sample time (hr) 16 17 18 19 20 0.0333 34.9 14.3 556 6.85 5.63 ATTORNEY DOCKET NO. 07341.020W01 Animal number Sample time (hr) 16 17 18 19 20 0.0666 18.2 48.4 368 27.2 12.8 0.1 117 73.5 105 384 57.9 0.122 125 88.1 124 788 73.4 0.167 133 89.3 130 703 76.3 0.25 135 156 131 231 79.0 0.5 137 225 150 227 81.4 0.75 156 108 70 204 1 46.4 107.6 53.4 81.0 52.7 2 17.6 23.4 11.9 21.6 16.3 Dose (mg/kg) 0.380 0.318 0.341 0.290 0.301 Giax (ng/mL) 156 225 150 788 tmax (hr) 0.750 0.50 0.50 0.133 0.750 t1/2 ND2 0.530 0.481 0.418 MRTiast (hr) 0.664 0.732 0.631 0.554 0.757 AUCiast (hr.ng/mL) 152 201 135 289 AUCco(hr.ng/mL) ND2 219 143 302 ND2 AUCiast/D

(hr.kg.ng/mL/mg) AUCco/D

(hr.kg.ng/mL/mg) 1. AUCiast/D (hr.kg.ng/mL/mg) and AUC./D (hr.kg.ng/mL/mg) are dose normalized values.
2. Not determined because the line defining the terminal elimination phase had an r2 of <0.85.
3. BLOQ = below the limit of quantitation (1 ng/mL) TABLE XI provides the mean and standard deviation for the results of Animals 11-21.
TABLE XI

ATTORNEY DOCKET NO. 07341.020W01 Sample time (hr) mean SD
0.0333 46.1 44.6 0.0666 108 108 0.1 201 156 0.122 240 226 0.167 207 198 0.25 234 140 0.5 245 158 0.75 145 52.1 1 73.4 19.3 2 24.6 8.83 Dose (mg/kg) 0.345 0.054 Giax (ng/mL) 367 220 tmax (hr) 0.423 0.232 t1/2 0.574 0.119 MRTIast (hr) 0.643 0.072 AUCiast (hr.ng/mL) 228 86.2 AUCco(hr.ng/mL) 271 88.5 AUCiast/D

(hr.kg.ng/mL/mg) AUCco/D

(hr.kg.ng/mL/mg) Figure 3 depicts the individual plasma concentrations (ng/mL) for Nicotine versus time (hour) after buccal administration of the disclosed nicotine benzoate composition disclosed in Table II (4 mg) in male Beagle dogs. Figure 4 shows the mean plasma concentration (ng/mL) for Nicotine versus time (hour) after buccal administration of the disclosed compound in Table II (4 mg) in male Beagle dogs.
Pharmacokinetic and Individual Plasma Concentrations (ng/mL) for Nicotine versus time (hour) after Buccal administration of nicotine polacrilex control composition disclosed in TABLES XII and XIII (4 mg) in Male Beagle dogs (Group 3) ATTORNEY DOCKET NO. 07341.020W01 TABLE XII
Animal number Sample time (hr) 21 22 23 24 25 0.0333 18.3 1.36 BLOQ BLOQ 1.146 0.0666 26.3 1.73 1.55 3.08 2.76 0.1 27.1 2.04 1.80 4.02 5.64 0.122 29.2 3.24 1.92 6.40 9.68 0.167 52.7 3.54 2.44 9.00

10.1 0.25 29.3 4.76 7.10 9.54

11.7 0.5 27.3 10.1 19.8 12.0 18.4 0.75 7.34 10.9 11.6 27.6 31.3 1 4.60 7.18 10.4 8.36 19.7 2 1.32 1.61 1.7 1.34 2.59 Dose (mg/kg) 0.290 0.303 0.264 0.266 0.317 Cmax (ng/M1) 52.7 10.9 19.8 27.6 31.3 tmax (hr) 0.167 0.750 0.50 0.750 0.750 t1/2 0.518 ND2 0.423 ND2 MRTiast (hr) 0.468 0.818 0.787 0.749 0.851 AUCiast (hr.ng/M1) 23.5 11.8 16.7 18.4 22.2 AUCco(hr.ng/M1) 24.5 ND2 17.7 ND2 AUCiast/D
81.0 39.0 63.3 69.2 81.4 (hr.kg.ng/Ml/mg) AUCco/D
84.4 ND2 67.2 ND2 (hr.kg.ng/Ml/mg) 1. AUCiast/D (hr.kg.ng/Ml/mg) and AUCco/D (hr.kg.ng/Ml/mg) are dose normalized values.
2. Not determined because the line defining the terminal elimination phase had an r2 of <0.85.
TABLE XIII

ATTORNEY DOCKET NO. 07341.020W01 Animal number Sample time (hr) 26 27 28 29 30 0.0333 BLOQ 1.60 BLOQ BLOQ BLOQ
0.0666 BLOQ 2.25 NS4 BLOQ 3.07 0.1 1.33 7.51 2.89 1.31 3.15 0.122 1.74 8.62 8.35 2.71 4.02 0.167 5.14 6.56 31.7 9.38 4.91 0.25 7.69 9.36 52.2 9.64 14.4 0.5 15.4 10.4 35.5 11.9 16.0 0.75 16.0 10.0 34.0 30.2 45.4 1 18.5 9.1 15.9 20.5 21.3 2 1.95 1.70 2.11 2.29 1.60 Dose (mg/kg) 0.272 0.363 0.400 0.290 0.484 C. (ng/mL) 18.5 10.4 52.2 30.2 45.4 tmax (hr) 1.00 0.50 0.250 0.750 0.750 t1/2 ND2 0.465 0.320 ND2 ND2 MRTiast (hr) 0.851 0.778 0.645 0.849 0.802 AUCiast (hr.ng/mL) 22.2 14.2 39.4 26.8 32.5 AUCco(hr.ng/mL) ND2 15.4 40.4 ND2 ND2 AUCiast/D
81.4 39.2 98.4 92.4 67.3 (hr.kg.ng/mL/mg) AUCco/D
ND2 42.3 100.8 ND2 ND2 (hr.kg.ng/mL/mg) 1. AUCiast/D (hr.kg.ng/mL/mg) and AUCco/D (hr.kg.ng/mL/mg) are dose normalized values.9.
2. Not determined because the line defining the terminal elimination phase had an r2 of <0.85.
3. BLOQ = below the limit of quantitation (1 ng/mL) TABLE XIV provides the mean and standard deviation for the results of Animals 30.

ATTORNEY DOCKET NO. 07341.020W01 TABLE XIV
Sample time (hr) mean SD
0.0333 5.58 8.48 0.0666 5.82 9.05 0.1 5.68 7.80 0.122 7.58 8.13 0.167 13.5 16.1 0.25 15.6 14.6 0.5 17.7 8.17 0.75 22.4 12.9 1 13.6 6.27 2 1.82 0.412 Dose (mg/kg) 0.325 0.071 Cmax (ng/mL) 29.9 15.8 tmax (hr) 0.617 0.258 t1/2 0.431 0.084 MRTIast (hr) 0.756 0.117 AUCiast (hr.ng/mL) 23.5 8.66 AUCco(hr.ng/mL) 24.5 11.3 AUCiast/D
72.3 21.0 (hr.kg.ng/mL/mg) AUCco/D
73.7 25.0 (hr.kg.ng/mL/mg) Figure 5 shows the individual plasma poncentrations (ng/mL) for Nicotine versus time (hour) after buccal administration of the nicotine polacrilex control composition disclosed in TABLE III (4 mg) in male Beagle dogs (Group 3). Figure 6 displays the mean plasma concentration (ng/mL) for Nicotine versus time (hour) after buccal administration of the nicotine polacrilex control composition disclosed in TABLE III (4 mg) in Male Beagle dogs (Group 3) ATTORNEY DOCKET NO. 07341.020W01 Pharmacokinetic Parameters and Plasma Concentrations (ng/mL) for Nicotine after Buccal Administration of pouches containing the nicotine polacrilex disclosed composition in TABLES XV and XVI (4 mg) in male Beagle dogs (Group 4) TABLE XV
Animal number Sample time (hr) 31 32 33 34 35 0.0333 5.50 18.9 192 5.26 2.05 0.0666 27.5 19.6 374 44.3 10.7 0.1 36.1 30.9 874 51.0 44.5 0.122 51.4 44.2 893 63.2 50.5 0.167 53.6 48.8 609 66.3 74.3 0.25 68.4 77.8 207 86.2 100 0.5 120 167 175 118 176 0.75 105 144 149 74.4 92.0 1 45.1 60.8 76.2 59.2 67.2 2 9.77 18.2 18.7 20.6 20.6 Dose (mg/kg) 0.242 0.304 0.327 0.314 0.304 C. (ng/mL) 120 167 893 118 176 tmax (hr) 0.500 0.500 0.133 0.500 0.500 .612 0.387 0.455 0.451 0.511 0.581 MRTtast (hr) 0.709 0.749 0.485 0.731 0.744 AUCiast (hr.ng/mL) 108 144 286 116 144 AUCco(hr.ng/mL) 113 156 298 126 161 AUCiast/D

(hr.kg.ng/mL/mg) AUC./D

(hr.kg.ng/mL/mg) 1. AUCiast/D (hr.kg.ng/mL/mg) and AUC./D (hr.kg.ng/mL/mg) are dose normalized values.

ATTORNEY DOCKET NO. 07341.020W01 2. Not determined because the line defining the terminal elimination phase had an r2 of <0.85.
TABLE XVI
Animal number Sample time (hr) 36 37 38 39 40 0.0333 8.03 9.83 13.2 11.1 3.67 0.0666 94.4 16.8 320 65.8 9.77 0.1 401 37.9 72.3 255 21.2 0.122 638 53.3 81.7 238 28.6 0.167 817 56.1 418 94.5 36.5 0.25 595 73.7 184 331 70.4 0.5 225 149 172 217 0.75 108 267 160 74 57.7 1 59.0 73.7 85.0 39.7 43.7 2 16.4 16.5 21.1 11.0 8.69 Dose (mg/kg) 0.311 0.358 0.345 0.336 0.319 Cmax (ng/mL) 817 267 418 331 tmax (hr) 0.167 0.750 0.167 0.250 0.500 t1/2 0.481 ND2 0.473 0.475 0.449 MRTiaat (hr) 0.443 0.795 0.662 0.495 0.700 AUCiast (hr.ng/mL) 313 183 209 193 97 AUCco(hr.ng/mL) 325 ND2 223 200 AUCiast/D

(hr.kg.ng/mL/mg) AUCco/D

(hr.kg.ng/mL/mg) 1. AUCiast/D (hr.kg.ng/mL/mg) and AUCco/D (hr.kg.ng/mL/mg) are dose normalized values.9.
2. Not determined because the line defining the terminal elimination phase had an r2 of <0.85.

ATTORNEY DOCKET NO. 07341.020W01 3. BLOQ = below the limit of quantitation (1 ng/mL).
TABLE XVII provides the mean and standard deviation for the results of Animals 40.
TABLE XVII
Sample time (hr) mean SD
0.0333 27.0 58.3 0.0666 73.6 116 0.1 182 273 0.122 214 302 0.167 242 297 0.25 179 169 0.5 166 36.2 0.75 123 61.3 1 60.9 15.0 2 16.5 5.66 Dose (mg/kg) 0.316 0.032 Cniax (ng/mL) 345 287 tmax (hr) 0.397 0.204 t1/2 0.474 0.052 MRTIast (hr) 0.651 0.127 AUCiast (hr.ng/mL) 1799 73.7 AUCco(hr.ng/mL) 190 79.6 AUCiast/D

(hr.kg.ng/mL/mg) AUCco/D

(hr.kg.ng/mL/mg) Figure 7 shows the individual plasma poncentrations (ng/mL) for Nicotine versus time (hour) after buccal administration of the nicotine polarcilex composition disclosed in TABLE
VI (4 mg) in male Beagle dogs (Group 4). Figure 8 discloses the mean plasma concentration ATTORNEY DOCKET NO. 07341.020W01 (ng/mL) for Nicotine versus time (hour) after buccal administration of the nicotine polarcrilex composition disclosed in TABLE VI (4 mg) in male Beagle dogs (Group 4).
PROCEDURES
Analytical Stock Solution Preparation Analytical stock solutions (1.00 mg/mL of the free drug) was prepared in water.
Standard Preparation Standards were prepared in blank male Beagle dog plasma. Working solutions were prepared in 50:50 acetonitrile:water. Working solutions were then added to plasma to make calibration standards to final concentrations of 2000, 1000, 500, 250, 100, 50, 10, 5, 2 and 1 ng/mL. Standards were treated identically to the study samples.
Sample Extraction Plasma samples were manually extracted via precipitation with acetonitrile in a 96-well plate.
Step Procedure 1 Standards: Add 10 pL of appropriate working solution to 50 uL of blank plasma.
Blanks: Add 10 uL of 50:50 (v:v) acetonitrile:water to 50 pL of blank plasma.
Samples: Add 10 [EL of 50:50 (v:v) acetonitrile:water to 50 L of plasma study sample.
2 Add 150 L of acetonitrile containing 20 ng/mL nicotine-d4 in acetonitrile as an internal standard. Cap and vortex.
3 Centrifuge samples at 4 C, at 3000 rpm for 5 minutes.
4 Transfer 125 I, supernatant and analysis by LC-MS/MS
HPLC Conditions Instrument: Waters Acquity UPLC
Column: Waters Phenyl BEH 1.7 um, 2.1 x 50 mm Aqueous Reservoir (A): lOmm Ammonium bicarbonate in water, pH 9.5 Organic Reservoir (B): Acetonitrile Gradient Program ATTORNEY DOCKET NO. 07341.020W01 Gradient Time (min.) % A % B
Curve 0.00 6 90 10 0.20 6 90 10 1.00 6 10 90 1.50 6 10 95 1.51 6 90 10 2.00 6 90 10 Flow Rate: 600 L/min Injection Volume: 3 L
Run Time: 2.0 min Column Temperature: 30 C
Sample Temperature: 4 C
Strong Autosampler Wash: 1:1:1:1 (v:v) acetonitrile:methanol:isopropanol:water Weak Autosampler Wash: 50:50 (v:v) methanol:water Mass Spectrometer Conditions Instrument: Waters Xevo TQ-MS
Interface: Electrospray Mode: Multiple Reaction Monitoring (MRM) Desolvation Gas: 1000 L/hr Cone Gas: 100 L/hr Collision Gas: 0.25 mL/min Desolvation Temp: 500 C
Capillary Voltage: 2.5 kV
While particular embodiments of the present disclosure have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the disclosure. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this disclosure.

Claims

What is claimed is:

1. A composition comprising:
a) from about 1% to about 6% by weight of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof;
b) from about 3% to about 20% by weight of sunflower oil;
c) from about 10% to about 20% by weight of sodium bicarbonate; and d) the balance one or more carriers.

2. The composition according to Claim 1, comprising nicotine.

3. The composition according to Claim 1, comprising a nicotine salt.

4. The composition according to Claim 1, comprising nicotine in cornbination with a resin.

5. The composition according to Claim 1, wherein the carrier is chosen from inulin, microcrystalline cellulose, galactogen, cellulose, chitin, pectin, psyllium, guar, hemicellulose, potato starch, or partially hydrolyzed polysaccharides.

6. The composition according to Claim 1, wherein the carrier is chosen from sorbitol, erythritol, xylitol, lactitol, maltitol, mannitol, hydrogenated starch hydrolysates, or isomaltose.

7. The composition according to Claim 1, further comprising glycerol, propylene glycol, f3-cyclodextrin, propylene glycol 400 (PEG 400), or mixtures thereof.

8. A composition, comprising:
a) from about 5 mg to about 50 mg by weight of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof;
b) from about 15 mg to about 160 mg by weight of sunflower oil; and c) from about 50 mg to about 300 mg by weight of sodium bicarbonate.

9. The composition according to Claim 8, comprising from 15 mg to about 40 mg by weight of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof.

10. The composition according to Claim 8, further comprising a carrier.

11. The composition according to Claim 10, wherein the carrier is chosen from inulin, microcrystalline cellulose, galactogen, cellulose, chitin, pectin, psyllium, guar, hemicellulose, potato starch, or partially hydrolyzed polysaccharides.

12. The composition according to Claim 10, wherein the carrier is chosen from sorbitol, erythritol, xylitol, lactitol, maltitol, mannitol, hydrogenated starch hydrolysates, or isomaltose.

13. The composition according to Claim 8, further comprising glycerol, propylene glycol, 0-cyclodextrin, propylene glycol 400 (PEG 400), or mixtures thereof.

14. A kit, comprising:
A) a liquid permeable pouch comprising a non-nicotine composition comprising:
a) one or more delivery control agents; and b) a bulking agent; and B) a base nicotine delivery composition comprising:
a) nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof;
b) sunflower oil;
c) sodium bicarbonate; and d) the balance one or more carriers.

15. The kit according to Claim 14, wherein the liquid permeable pouch comprises wheat fibers, oat fibers, pea fibers, rice fiber, maize fibers, oat fibers, tomato fibers, barley fibers, rye fibers, sugar beet fibers, buckwheat fibers, potato fibers, cellulose fibers, apple fibers, cocoa fibers, cellulose fiber, powdered cellulose, bamboo fibers, bran fibers or combinations thereof.

16. The kit according to Claim 15, comprising:
B) frorn about 70 mg to about 510 mg of an active base delivery system, comprising:
a) from about 5 mg to about 50 mg by weight of nicotine benzoate;
b) from about 15 mg to about 160 mg by weight of sunflower oil;
c) from about 50 mg to about 300 mg by weight of sodium bicarbonate;
d) from about 350 mg to about 1500 mg of one or more carriers; and e) the balance one or more delivery control agents.

17. The kit according to Claim 16, wherein the carrier is chosen from inulin, microcrystalline cellulose, galactogen, cellulose, chitin, pectin, psyllium, guar, hemicellulose, potato starch, or partially hydrolyzed polysaccharides.

18. The kit according to Claim 16, wherein the carrier is chosen from sorbitol, erythritol, xylitol, lactitol, maltitol, mannitol, hydrogenated starch hydrolysates, or isomaltose.

19. The kit according to Claim 16, wherein the one or more carriers is a bulking agent chosen form dextrin, microcrystalline cellulose, inulin, and mixtures thereof.

20. The kit according to Claim 16, wherein the delivery control agent is chosen from glycerol, propylene glycol, b-cyclodextrin and propylene glycol 400 (PEG 400).

21. The kit according to Claim 14, comprising:
B) frorn about 70 mg to about 510 mg of an active base composition, comprising:
a) from about 5 mg to about 50 mg by weight of nicotine polacrilex;
b) from about 15 mg to about 160 mg by weight of sunflower oil;
c) from about 50 mg to about 300 mg by weight of sodium bicarbonate;
cl) from about 350 mg to about 1500 mg of one or more carriers; and e) the balance one or more delivery control agents.

22. The kit according to Claim 21, wherein the carrier is chosen from inulin, microcrystalline cellulose, galactogen, cellulose, chitin, pectin, psyllium, guar, hemicellulose, potato starch, or partially hydrolyzed polysaccharides.

23. The kit according to Claim 21, wherein the carrier is chosen from sorbitol, erythritol, xylitol, lactitol, maltitol, mannitol, hydrogenated starch hydrolysates, or isomaltose.

24. The kit according to Claim 21, wherein the one or more carriers is a bulking agent chosen form dextrin, microcrystalline cellulose, inulin, and mixtures thereof.

25. The kit according to Claim 21, wherein the delivery control agent is chosen from glycerol, propylene glycol, b-cyclodextrin and propylene glycol 400 (PEG 400).

26. A composition, comprising:
a) from about 8.6 mg to about 21.7 mg of nicotine, a nicotine salt, nicotine in combination with a resin, or mixtures thereof;
b) from about 25.8 to about 72.6 mg of sunflower oil; and c) from about 76.1 mg to about 86.6 mg of sodium bicarbonate.

27. The composition according to Claim 26, wherein the nicotine salt is nicotine benzoate and the nicotine in combination with a resin is nicotine polacrilex.

28. The composition according to Claim 26, further comprising from about 383.2 mg to about 510 mg of inulin.

29. The composition according to Claim 26, comprising nicotine polacrilex.

30. The composition according to Claim 29, further comprising glycerin.